Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-Versus-Host Disease

Ruxolitinib treatment for GvHD in patients with myelofibrosis

Bone Marrow Transplantation volume 51, pages 1584–1587 (2016)Cite this article

Subjects

Abstract

Jak1/2 inhibitor ruxolitinib is a promising agent for treating steroid-refractory GvHD after allogeneic hematopoietic stem cell transplantation (SCT) to produce quick and durable responses. However, optimal dose and tapering schedule of ruxolitinib remain to be determined. Discontinuation of ruxolitinib in myelofibrosis often induces ‘withdrawal syndrome’ characterized by acute relapse of the disease, but this issue is not well addressed in the treatment of GvHD. Four patients with GvHD (one acute and three chronic) after SCT for myelofibrosis were treated with ruxolitinib. Low-dose ruxolitinib at 5 mg/day was safe and effective, but one of two patients treated at 10 mg/day of ruxolitinib was complicated with severe cytopenia. Withdrawal syndrome developed in one patient, who died of recurrence of GvHD shortly after discontinuation of ruxolitinib. Slow tapering or maintenance with low-dose ruxolitinib inhibited GvHD flare. Our experience calls attention that initiation at low-dose of ruxolitinib may be safe and careful tapering schedule is required to avoid withdrawal syndrome in patients with GvHD after SCT for myelofibrosis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Holler E, Kolb HJ, Moller A, Kempeni J, Lisenfeld S, Pechumer H et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990; 75: 1011–1016.

    CAS  PubMed  Google Scholar 

  2. Hill GR, Crawford JM, Cooke KJ, Brinson YS, Pan L, Ferrara JLM . Total body irradiation and acute graft versus host disease. The role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90: 3204–3213.

    CAS  PubMed  Google Scholar 

  3. Hill GR, Ferrara JL . The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000; 95: 2754–2759.

    CAS  PubMed  Google Scholar 

  4. Teshima T, Ordemann R, Reddy P, Gagin S, Liu C, Cooke KR et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002; 8: 575–581.

    Article  CAS  PubMed  Google Scholar 

  5. Xhaard A, Rocha V, Bueno B, de Latour RP, Lenglet J, Petropoulou A et al. Steroid-refractory acute GVHD: lack of long-term improved survival using new generation anticytokine treatment. Biol Blood Marrow Transplant 2012; 18: 406–413.

    Article  CAS  PubMed  Google Scholar 

  6. Antin JH, Weisdorf D, Neuberg D, Nicklow R, Clouthier S, Lee SJ et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 2002; 100: 3479–3482.

    Article  CAS  PubMed  Google Scholar 

  7. Alousi AM, Weisdorf DJ, Logan BR, Bolanos-Meade J, Carter S, Difronzo N et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009; 114: 511–517.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A . The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 2015; 66: 311–328.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Teshima T, Reddy P, Zeiser R . Acute Graft-versus-Host Disease: Novel Biological Insights. Biol Blood Marrow Transplant 2016; 22: 11–16.

    Article  CAS  PubMed  Google Scholar 

  10. Spoerl S, Mathew NR, Bscheider M, Schmitt-Graeff A, Chen S, Mueller T et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood 2014; 123: 3832–3842.

    Article  CAS  PubMed  Google Scholar 

  11. Teshima T . JAK inhibitors: a home run for GVHD patients? Blood 2014; 123: 3691–3693.

    Article  CAS  PubMed  Google Scholar 

  12. Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 2015; 29: 2062–2068.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Heine A, Brossart P, Wolf D . Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood 2013; 122: 3843–3844.

    Article  CAS  PubMed  Google Scholar 

  14. Tefferi A, Pardanani A . Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 2011; 86: 1188–1191.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799–807.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366: 787–798.

    Article  CAS  PubMed  Google Scholar 

  17. Dignan FL, Amrolia P, Clark A, Cornish J, Jackson G, Mahendra P et al. Diagnosis and management of chronic graft-versus-host disease. Br J Haematol 2012; 158: 46–61.

    Article  CAS  PubMed  Google Scholar 

  18. Flowers ME, Martin PJ . How we treat chronic graft-versus-host disease. Blood 2015; 125: 606–615.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

    Y Mori & G Yoshimoto

  2. Department of Cardiology and Hematology, Fukushima, Japan

    K Ikeda

  3. Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University, Fukushima, Japan

    K Ikeda

  4. Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan

    T Inomata & N Fujii

  5. Division of Hematology and Oncology, Shimane Prefectural Central Hospital, Izumo, Japan

    H Ago

  6. Department of Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

    T Teshima

Authors
  1. Y Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Inomata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Yoshimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N Fujii
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H Ago
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T Teshima
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Teshima.

Ethics declarations

Competing interests

TT has consultancy from Novartis Oncology. The remaining authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mori, Y., Ikeda, K., Inomata, T. et al. Ruxolitinib treatment for GvHD in patients with myelofibrosis. Bone Marrow Transplant 51, 1584–1587 (2016). https://doi.org/10.1038/bmt.2016.256

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.256

This article is cited by

Search

Advanced search

Quick links